GPHL Announces RMB 50 Billion Five-Year Plan to 'Recreate GPHL' with Huawei AI

On August 12, 2026, at the 19th Health Industry Ecosystem Conference, GPHL General Manager Chen Jiehui announced that the group has set the strategic goal of "recreating a GPHL" for the 15th Five-Year Plan period, with digital industrialization and industrial digitalization serving as the dual engines supporting this objective. GPHL has established a "4+4+X" business development structure, encompassing four cornerstone sectors: modern traditional Chinese medicine, chemical pharmaceutical technology, pharmaceutical commerce, and natural beverages; four growth sectors: biotech innovation, consumer health, diagnostics and equipment, and agricultural technology; and extended sectors including asset operations and medical services.

Zheng Jianxiong, deputy general manager of GPHL Baiyunshan, said the group has intensified AI applications in new drug R&D, channel management, and marketing. In drug development, GPHL has partnered with Huawei to build a pharmaceutical-specific, self-controlled AI computing foundation based on the Ascend series, with core metrics such as molecular sampling and drug structure prediction surpassing comparable international solutions, while establishing a standardized pathway for domestic computing power to serve the pharmaceutical industry. The group has formulated a "2026-2028 three-step" intelligent upgrade plan aimed at improving AI-driven lead molecule mining efficiency, closing the dry-wet experiment data loop, and accumulating proprietary pharmaceutical databases and self-developed AI model assets.

Over the next five years, GPHL plans to invest RMB 20 billion in technology R&D and RMB 30 billion in acquisitions and pipeline cooperation, providing systematic investment to ensure the realization of the "Recreate a GPHL" strategy. Chen Jiehui said the group will deepen its "4+4+X" business structure, uphold technology-driven innovation, and accelerate its global expansion.